NSCLC – Medxy AI

Updated Phase III HARMONi Trial Data Reveal Enhanced Survival Benefits of Ivonescimab in NSCLC

By MedXY 09/07/2025

Recent updates from the global Phase III HARMONi study demonstrate envafolimab’s significant improvement in overall and progression-free survival in NSCLC, with consistent benefits across diverse populations, reinforcing its emerging role in lung cancer therapy.

Clinical Updates Wellness & Lifestyle

High-Dose Vitamin C Induces Pyroptosis in LKB1-Mutant Lung Cancer and Enhances Immunotherapy Response

By MedXY 08/23/2025

New research reveals that high-dose vitamin C selectively kills LKB1-mutant NSCLC cells by inducing pyroptosis, reversing immunotherapy resistance and improving T cell infiltration through GLUT1-mediated uptake and ROS-mediated cell death.

Clinical Updates Wellness & Lifestyle

Comparative Efficacy and Safety of Limertinib versus Gefitinib in First-Line Treatment of EGFR-Mutated Advanced NSCLC: A Phase 3 Randomized Trial

By MedXY 08/02/2025

Limertinib demonstrates superior progression-free survival and a comparable safety profile to gefitinib, supporting its use as a first-line therapy in EGFR-mutated locally advanced or metastatic NSCLC.